Back to Search Start Over

Endovascular thrombectomy for ischemic stroke increases disability-free survival, quality of life, and life expectancy and reduces cost.

Authors :
Ma H.
Chandra R.V.
Bladin C.F.
Rice H.
de Villiers L.
Desmond P.M.
Meretoja A.
Cadilhac D.A.
Donnan G.A.
Davis S.M.
Campbell B.C.V.
Mitchell P.J.
Churilov L.
Keshtkaran M.
Hong K.-S.
Kleinig T.J.
Dewey H.M.
Yassi N.
Yan B.
Dowling R.J.
Parsons M.W.
Wu T.Y.
Brooks M.
Simpson M.A.
Miteff F.
Levi C.R.
Krause M.
Harrington T.J.
Faulder K.C.
Steinfort B.S.
Ang T.
Scroop R.
Barber P.A.
McGuinness B.
Wijeratne T.
Phan T.G.
Chong W.
Ma H.
Chandra R.V.
Bladin C.F.
Rice H.
de Villiers L.
Desmond P.M.
Meretoja A.
Cadilhac D.A.
Donnan G.A.
Davis S.M.
Campbell B.C.V.
Mitchell P.J.
Churilov L.
Keshtkaran M.
Hong K.-S.
Kleinig T.J.
Dewey H.M.
Yassi N.
Yan B.
Dowling R.J.
Parsons M.W.
Wu T.Y.
Brooks M.
Simpson M.A.
Miteff F.
Levi C.R.
Krause M.
Harrington T.J.
Faulder K.C.
Steinfort B.S.
Ang T.
Scroop R.
Barber P.A.
McGuinness B.
Wijeratne T.
Phan T.G.
Chong W.
Publication Year :
2017

Abstract

Background: Endovascular thrombectomy improves functional outcome in large vessel occlusion ischemic stroke. We examined disability, quality of life, survival and acute care costs in the EXTEND-IA trial, which used CT-perfusion imaging selection. Method(s): Large vessel ischemic stroke patients with favorable CT-perfusion were randomized to endovascular thrombectomy after alteplase versus alteplase-only. Clinical outcome was prospectively measured using 90-day modified Rankin scale (mRS). Individual patient expected survival and net difference in Disability/Quality-adjusted life years (DALY/QALY) up to 15 years from stroke were modeled using age, sex, 90-day mRS, and utility scores. Level of care within the first 90 days was prospectively measured and used to estimate procedure and inpatient care costs (US$ reference year 2014). Result(s): There were 70 patients, 35 in each arm, mean age 69, median NIHSS 15 (IQR 12-19). The median (IQR) disability-weighted utility score at 90 days was 0.65 (0.00-0.91) in the alteplase-only versus 0.91 (0.65-1.00) in the endovascular group (p = 0.005). Modeled life expectancy was greater in the endovascular versus alteplase-only group (median 15.6 versus 11.2 years, p = 0.02). The endovascular thrombectomy group had fewer simulated DALYs lost over 15 years [median (IQR) 5.5 (3.2-8.7) versus 8.9 (4.7-13.8), p = 0.02] and more QALY gained [median (IQR) 9.3 (4.2-13.1) versus 4.9 (0.3-8.5), p = 0.03]. Endovascular patients spent less time in hospital [median (IQR) 5 (3-11) days versus 8 (5-14) days, p = 0.04] and rehabilitation [median (IQR) 0 (0-28) versus 27 (0-65) days, p = 0.03]. The estimated inpatient costs in the first 90 days were less in the thrombectomy group (average US$15,689 versus US$30,569, p = 0.008) offsetting the costs of interhospital transport and the thrombectomy procedure (average US$10,515). The average saving per patient treated with thrombectomy was US$4,365. Conclusion(s): Thrombectomy patients with large vessel

Details

Database :
OAIster
Publication Type :
Electronic Resource
Accession number :
edsoai.on1305113414
Document Type :
Electronic Resource